Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
| Revenue (TTM) | $535.08M |
| Gross Profit (TTM) | $427.95M |
| EBITDA | $-49.02M |
| Operating Margin | -3.78% |
| Return on Equity | -14.00% |
| Return on Assets | -5.87% |
| Revenue/Share (TTM) | $12.54 |
| Book Value | $8.11 |
| Price-to-Book | 7.52 |
| Price-to-Sales (TTM) | 4.81 |
| EV/Revenue | 4.311 |
| EV/EBITDA | -3.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 106.90% |
| Shares Outstanding | $43.63M |
| Float | $32.11M |
| % Insiders | 3.06% |
| % Institutions | 109.84% |
Volatility is currently contracting
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TARS experienced a dip in net product sales in Q1'26, relative to Q4'25, the first decrease since Xdemvy launched. TARS reiterates 2026 Xdemvy net sales guidance of $670M–$700M, with Q2'26 prescription data indicating a potential recovery in Xdemvy and the ability to meet 2026 guidance. The iRenix Medical acquisition expands the pipeline with IRX-101, an ocular antiseptic, though revenues are several years out.
IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor.
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care
Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per share amid sector-wide healthcare weakness. Xdemvy's Q1 sales more than doubled YoY, but unchanged 2026 revenue guidance ($670–$700M) disappointed, implying 18% annualized growth from the current quarterly run-rate. TARS is building a robust distribution moat, with nearly half of targeted ECPs prescribing Xdemvy weekly and direct-to-consumer activation up 40% QoQ.
IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by microscopic mites that live in and around the eyelashes. Cena's story reflects the experience of millions who live with symptoms for years before seeking care and receiving a proper diagnosis.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TARS and any ticker you trade — then tracks every position and per-strategy win rate.
